Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
The 2026 FIFA World Cup is more than just a tournament. With over 6.5 million fans expected to attend, it's become one of the world's largest economic events.
Variety Senior TV Editor Brian Steinberg breaks down media mergers, streaming, cord-cutting, and the biggest trends reshaping the future of television.
As AI demand surges, LT350 is reimagining parking lots as data centers. Founder and CEO Jeff Thramann explains this innovative approach to AI infrastructure.
TIME Editorial Director Lucy Feldman breaks down the 2026 TIME100 Creators list, the evolution of the creator economy, and what's next for digital media.
Can blockbuster movies and streaming thrive together? Paul Dergarabedian breaks down The Odyssey's record box office, Netflix's earnings, and Hollywood's future
